ALT5 Sigma Corporation (NASDAQ:ALTS - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock traders acquired 8,298 call options on the stock. Thisisanincreaseof597% compared to the typical volume of 1,190 call options.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALTS. Geode Capital Management LLC boosted its holdings in shares of ALT5 Sigma by 27.6% in the 2nd quarter. Geode Capital Management LLC now owns 194,813 shares of the company's stock valued at $1,412,000 after buying an additional 42,157 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ALT5 Sigma in the 2nd quarter valued at approximately $380,000. Bridgeway Capital Management LLC raised its position in shares of ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company's stock valued at $140,000 after purchasing an additional 1,661 shares during the last quarter. Finally, Evernest Financial Advisors LLC purchased a new position in shares of ALT5 Sigma in the 2nd quarter valued at approximately $87,000. 6.27% of the stock is currently owned by institutional investors.
ALT5 Sigma Stock Performance
Shares of ALTS traded up $0.01 during midday trading on Monday, hitting $5.95. The stock had a trading volume of 2,920,196 shares, compared to its average volume of 1,138,751. ALT5 Sigma has a 1 year low of $1.55 and a 1 year high of $10.95. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.45. The stock's 50 day moving average is $7.84 and its 200 day moving average is $6.60.
Analyst Ratings Changes
Separately, Wall Street Zen cut ALT5 Sigma from a "hold" rating to a "strong sell" rating in a research report on Saturday.
View Our Latest Research Report on ALTS
About ALT5 Sigma
(
Get Free Report)
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.
Further Reading
Before you consider ALT5 Sigma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALT5 Sigma wasn't on the list.
While ALT5 Sigma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access